Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Seagen Inc
(NQ:
SGEN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Seagen Inc
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March?
April 19, 2023
A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating...
Via
Benzinga
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
Via
Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years
April 18, 2023
Via
Benzinga
Consider This Undervalued Pharma Giant Before Its Blockbuster Deal Closes
April 17, 2023
Wall Street isn't showing one of pharma's most prominent players any love.
Via
The Motley Fool
Is Pfizer Stock a Buy, Sell or Hold? Here’s My Call.
April 06, 2023
Pfizer can't depend on Covid-19 vaccines as a revenue source in 2023, but PFE stock can still grow as the drugmaker broadens its pipeline.
Via
InvestorPlace
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years
April 03, 2023
Via
Benzinga
Analyst Ratings for Seagen
March 24, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years
March 15, 2023
Via
Benzinga
A Bullish Sign Appears On Seagen's Chart
March 14, 2023
Via
Benzinga
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
April 04, 2023
Via
Benzinga
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
March 29, 2023
Viking Therapeutics stock might in the midst of a historic run.
Via
The Motley Fool
It's Not Tesla, Meta Or Nvidia — The Best Performing Large-Cap Stock In 2023 Is A Crypto Play
March 27, 2023
The SPDR S&P 500 ETF Trust (NYSE: SPY) has seen a positive return in 2023. Several sectors are in the green so far this year, and many well-known stocks are among the biggest gainers. Here’s a look at...
Via
Benzinga
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
March 27, 2023
Via
Benzinga
3 Low P/E Stocks That Are Bound to Rebound This Year
March 27, 2023
These are the low P/E stocks to buy at current levels for a sharp reversal rally in the coming quarters.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
March 24, 2023
Via
Benzinga
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
March 22, 2023
Pfizer's stock remains down despite its latest dealmaking, but it may only be a matter of time before it starts to rally.
Via
The Motley Fool
Pfizer Has Another Blockbuster on the Horizon, but That's Not All
March 21, 2023
The drugmaker continues to grab headlines for the right reasons.
Via
The Motley Fool
1 Top Healthcare Stock That Could Make You Richer in the Next Decade
March 19, 2023
The Pfizer of tomorrow will be larger and even more lucrative to hold than it is now.
Via
The Motley Fool
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
March 18, 2023
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had...
Via
Talk Markets
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
March 17, 2023
A market rally is underway, but bank stocks kept tumbling.
Via
Investor's Business Daily
This Must-Buy Dividend Growth Stock Could Pay You for Life
March 16, 2023
It might not regularly beat the market, but it won't have any trouble padding your wallet.
Via
The Motley Fool
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
March 16, 2023
It's time for another dive into the biggest pre-market stock movers as we go over all the latest news for Thursday morning!
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2023
March 15, 2023
Via
Benzinga
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines
March 15, 2023
Under Joe Biden's signature Inflation Reduction Act, drugmakers for twenty-seven drugs will be penalized for charging prices that rise faster than inflation for people with disabilities or the elderly...
Via
Benzinga
Meta Platforms To Rally Over 36%? Here Are 10 Other Analyst Forecasts For Wednesday
March 15, 2023
Credit Suisse cut the price target for Zscaler, Inc. (NASDAQ: ZS) from $275 to $165. Credit Suisse analyst Sami Badri maintained an Outperform rating. Zscaler shares fell 1.9% to $105.95 in pre-market...
Via
Benzinga
Does This Billion-Dollar Deal Solve Pfizer's Biggest Problem?
March 14, 2023
Pfizer's planned acquisition of Seagen could be a very important move.
Via
The Motley Fool
Key Inflation Meter Doesn't Show New Signs for Concern and Stocks Begin Shaking Off Instability
March 14, 2023
(Tuesday Market Open) The first of this week’s three critical data releases, February’s Consumer Price Index (CPI), was pretty much in line with expectations Tuesday, perhaps easing some concerns about...
Via
Benzinga
Is Pfizer Stock a Screaming Buy After Its $43 Billion Seagen Acquisition?
March 14, 2023
Pfizer's $43 billion Seagen acquisition is a long-term value-creation strategy.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
March 14, 2023
Via
Benzinga
These Analysts Boost Price Targets On Seagen Following Acquisition News
March 14, 2023
Pfizer Inc (NYSE: PFE) agreed to acquire Seagen Inc (NASDAQ: SGEN) for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen shares jumped 14.5% to close at $197.65 on...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.